Emergent Biosolutions Stock Profit Margin
| EBS Stock | USD 6.11 0.41 7.19% |
Emergent Biosolutions fundamentals help investors to digest information that contributes to Emergent Biosolutions' financial success or failures. It also enables traders to predict the movement of Emergent Stock. The fundamental analysis module provides a way to measure Emergent Biosolutions' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Emergent Biosolutions stock.
| Last Reported | Projected for Next Year | ||
| Net Loss | (0.72) | (0.69) |
Emergent | Profit Margin |
Emergent Biosolutions Company Profit Margin Analysis
Emergent Biosolutions' Profit Margin measures overall efficiency of a company and shows its ability to withstand competition as well as defend against adverse conditions such as rising costs, falling prices, decline in sales or management distress. Profit margin tells investors how well the company executes on its overall pricing strategies as well as how effective the company in controlling its costs.
Current Emergent Biosolutions Profit Margin | (0.48) % |
Most of Emergent Biosolutions' fundamental indicators, such as Profit Margin, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Emergent Biosolutions is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Emergent Profit Margin Driver Correlations
Understanding the fundamental principles of building solid financial models for Emergent Biosolutions is extremely important. It helps to project a fair market value of Emergent Stock properly, considering its historical fundamentals such as Profit Margin. Since Emergent Biosolutions' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Emergent Biosolutions' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Emergent Biosolutions' interrelated accounts and indicators.
In a nutshell, Profit Margin indicator shows the amount of money the company makes from total sales or revenue. It can provide a good insight into companies in the same sector, as well as help to identify trends of a company from year to year.
| Competition |
Emergent Pretax Profit Margin
Pretax Profit Margin |
|
Based on the latest financial disclosure, Emergent Biosolutions has a Profit Margin of -0.4769%. This is 95.75% lower than that of the Biotechnology sector and significantly lower than that of the Health Care industry. The profit margin for all United States stocks is 62.45% lower than that of the firm.
Did you try this?
Run Investing Opportunities Now
Investing OpportunitiesBuild portfolios using our predefined set of ideas and optimize them against your investing preferences |
| All Next | Launch Module |
Emergent Biosolutions ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Emergent Biosolutions' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Emergent Biosolutions' managers, analysts, and investors.Environmental | Governance | Social |
Emergent Fundamentals
| Return On Equity | -0.61 | ||||
| Return On Asset | -0.0038 | ||||
| Profit Margin | (0.48) % | ||||
| Operating Margin | 0.13 % | ||||
| Current Valuation | 1.16 B | ||||
| Shares Outstanding | 52.4 M | ||||
| Shares Owned By Insiders | 2.17 % | ||||
| Shares Owned By Institutions | 69.97 % | ||||
| Number Of Shares Shorted | 6.04 M | ||||
| Price To Earning | 1.67 X | ||||
| Price To Book | 0.17 X | ||||
| Price To Sales | 0.10 X | ||||
| Revenue | 1.12 B | ||||
| Gross Profit | 290.1 M | ||||
| EBITDA | (34.4 M) | ||||
| Net Income | (223.8 M) | ||||
| Cash And Equivalents | 642.6 M | ||||
| Cash Per Share | 7.28 X | ||||
| Total Debt | 1.41 B | ||||
| Debt To Equity | 0.56 % | ||||
| Current Ratio | 3.92 X | ||||
| Book Value Per Share | 12.67 X | ||||
| Cash Flow From Operations | (34.1 M) | ||||
| Short Ratio | 0.62 X | ||||
| Earnings Per Share | (10.97) X | ||||
| Price To Earnings To Growth | 1.55 X | ||||
| Target Price | 5.0 | ||||
| Number Of Employees | 1.6 K | ||||
| Beta | 1.24 | ||||
| Market Capitalization | 320.18 M | ||||
| Total Asset | 3.17 B | ||||
| Retained Earnings | 734 M | ||||
| Working Capital | 28.2 M | ||||
| Current Asset | 537.41 M | ||||
| Current Liabilities | 99.61 M | ||||
| Net Asset | 3.17 B |
About Emergent Biosolutions Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Emergent Biosolutions's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Emergent Biosolutions using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Emergent Biosolutions based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Emergent Biosolutions
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Emergent Biosolutions position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Emergent Biosolutions will appreciate offsetting losses from the drop in the long position's value.Moving together with Emergent Stock
Moving against Emergent Stock
| 0.84 | EXEL | Exelixis | PairCorr |
| 0.78 | FENC | Fennec Pharmaceuticals | PairCorr |
| 0.72 | GLUE | Monte Rosa Therapeutics | PairCorr |
| 0.69 | RVPHW | Reviva Pharmaceuticals | PairCorr |
| 0.61 | HOWL | Werewolf Therapeutics | PairCorr |
The ability to find closely correlated positions to Emergent Biosolutions could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Emergent Biosolutions when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Emergent Biosolutions - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Emergent Biosolutions to buy it.
The correlation of Emergent Biosolutions is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Emergent Biosolutions moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Emergent Biosolutions moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Emergent Biosolutions can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Emergent Stock Analysis
When running Emergent Biosolutions' price analysis, check to measure Emergent Biosolutions' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Emergent Biosolutions is operating at the current time. Most of Emergent Biosolutions' value examination focuses on studying past and present price action to predict the probability of Emergent Biosolutions' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Emergent Biosolutions' price. Additionally, you may evaluate how the addition of Emergent Biosolutions to your portfolios can decrease your overall portfolio volatility.